Stock NTBL NOTABLE LABS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Notable Labs, Ltd.

Equities

NTBL

IL0012002452

End-of-day quote Nasdaq
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
1.25 USD -15.54% Intraday chart for Notable Labs, Ltd. +31.58% -33.86%
04-15 Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating MT
04-15 Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
AQ
VASR BIOG : Notable Corporate Presentation
PU
Notable Labs Reports 2023 Financial Results and Provides a Business Update
AQ
Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating
MT
Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating
MT
Notable Labs Reports 2023 Financial Results and Provides a Business Update
AQ
VASR BIOG : AACR 2024 VOLA Poster
PU
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
AQ
Notable Labs, Ltd. Presents the Design Plan for the Ppmp-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
CI
VASR BIOG : AACR 2024 Poster
PU
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
AQ
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay At AACR 2024 Expands the Potential of the Platform
CI
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
AQ
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
AQ
Notable Labs, Ltd. Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
CI
Top Premarket Gainers
MT
JMP Securities Cuts Notable Labs' Price Target to $9 From $13, Keeps Market Outperform Rating
MT
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome
AQ
Notable Labs, Ltd. and CicloMed LLC Announces Initial Safety and Efficacy Data of Fosciclopirox and the Performance of PPMP
CI
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTBL Stock
  4. News Notable Labs, Ltd.